Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)

PJ Gallagher; C McGuigan; R Nicholas; J Hobart; H Ford; K Petheram; B Sharrack; N Robertson; G Mazibrada; N Scolding; M Wilson; O Pearson; E Silber; D Rog; B Turner; S Harikrishnan; M Duddy; O Gray; J Jones; J Overell; MS ANSWERS

doi:10.1177/1352458517731404

Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)

PJ Gallagher
, C McGuigan
, R Nicholas
, J Hobart
, H Ford
, K Petheram
, B Sharrack
, N Robertson
, G Mazibrada
, N Scolding
, M Wilson
, O Pearson
, E Silber
, D Rog
, B Turner
, S Harikrishnan
, M Duddy
, O Gray
, J Jones
, J Overell

MS ANSWERS

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1177/1352458517731404
Publication status	Published - Oct 2017

Access to Document

10.1177/1352458517731404

Cite this

Gallagher, PJ., McGuigan, C., Nicholas, R., Hobart, J., Ford, H., Petheram, K., Sharrack, B., Robertson, N., Mazibrada, G., Scolding, N., Wilson, M., Pearson, O., Silber, E., Rog, D., Turner, B., Harikrishnan, S., Duddy, M., Gray, O., Jones, J., ... ANSWERS, MS. (2017). Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS). https://doi.org/10.1177/1352458517731404

@conference{8b50d8b8e96545b396266a2fb40ba28d,

title = "Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)",

author = "PJ Gallagher and C McGuigan and R Nicholas and J Hobart and H Ford and K Petheram and B Sharrack and N Robertson and G Mazibrada and N Scolding and M Wilson and O Pearson and E Silber and D Rog and B Turner and S Harikrishnan and M Duddy and O Gray and J Jones and J Overell and MS ANSWERS",

year = "2017",

month = oct,

doi = "10.1177/1352458517731404",

language = "English",

}

Gallagher, PJ, McGuigan, C, Nicholas, R, Hobart, J, Ford, H, Petheram, K, Sharrack, B, Robertson, N, Mazibrada, G, Scolding, N, Wilson, M, Pearson, O, Silber, E, Rog, D, Turner, B, Harikrishnan, S, Duddy, M, Gray, O, Jones, J, Overell, J & ANSWERS, MS 2017, 'Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)'. https://doi.org/10.1177/1352458517731404

TY - CONF

T1 - Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)

AU - Gallagher, PJ

AU - McGuigan, C

AU - Nicholas, R

AU - Hobart, J

AU - Ford, H

AU - Petheram, K

AU - Sharrack, B

AU - Robertson, N

AU - Mazibrada, G

AU - Scolding, N

AU - Wilson, M

AU - Pearson, O

AU - Silber, E

AU - Rog, D

AU - Turner, B

AU - Harikrishnan, S

AU - Duddy, M

AU - Gray, O

AU - Jones, J

AU - Overell, J

AU - ANSWERS, MS

PY - 2017/10

Y1 - 2017/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413730202115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008

U2 - 10.1177/1352458517731404

DO - 10.1177/1352458517731404

M3 - Conference paper (not formally published)

ER -

Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)

Access to Document

Other files and links

Cite this